Literature DB >> 14506913

Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin.

Christopher J Fowler1, Gunnar Tiger, María L López-Rodríguez, Alma Viso, Silvia Ortega-Gutiérrez, José A Ramos.   

Abstract

Arachidonoyl-serotonin inhibits in a mixed-type manner the metabolism of the endocannabinoid anandamide by the enzyme fatty acid amidohydrolase. In the present study, compounds related to arachidonoyl-serotonin have been synthesised and investigated for their ability to inhibit anandamide hydrolysis by this enzyme in rat brain homogenates. Removal of the 5-hydroxy from the serotonin head group of arachidonoyl-serotonin produced a compound (N-arachidonoyltryptamine) that was a 2.3-fold weaker inhibitor of anandamide hydrolysis, but which also produced its inhibition by a mixed-type manner (Ki(slope) 1.3 microM; Ki(intercept) 44 microM). Replacement of the amide linkage in this compound by an ester group further reduced the potency. In contrast, replacement of the arachidonoyl side chain by a linolenoyl side chain did not affect the observed potency. N-(Fur-3-ylmethyl) arachidonamide (UCM707), N-(fur-3-ylmethyl)linolenamide and N-(fur-3-ylmethyl)oleamide inhibited anandamide hydrolysis with pI50 values of 4.53, 5.36 and 5.25, respectively. The linolenamide derivative was also found to be a mixed-type inhibitor. It is concluded that the 5-hydroxy group of arachidonoyl-serotonin contributes to, but is not essential for, inhibitory potency at fatty acid amidohydrolase.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506913     DOI: 10.1080/1475636031000080216

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  5 in total

Review 1.  The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1.

Authors:  C J Fowler; P S Naidu; A Lichtman; V Onnis
Journal:  Br J Pharmacol       Date:  2009-02       Impact factor: 8.739

2.  Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors.

Authors:  S Maione; L De Petrocellis; V de Novellis; A Schiano Moriello; S Petrosino; E Palazzo; F Sca Rossi; D F Woodward; V Di Marzo
Journal:  Br J Pharmacol       Date:  2007-02-05       Impact factor: 8.739

3.  Inhibition of human recombinant T-type calcium channels by N-arachidonoyl 5-HT.

Authors:  Andrew J Gilmore; Marika Heblinski; Aaron Reynolds; Michael Kassiou; Mark Connor
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

4.  Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study.

Authors:  Lidia Ruiz-Llorente; Silvia Ortega-Gutiérrez; Alma Viso; María G Sánchez; Ana M Sánchez; Carlos Fernández; José A Ramos; Cecilia Hillard; Miguel A Lasunción; María L López-Rodríguez; Inés Díaz-Laviada
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

Review 5.  Dual-Acting Compounds Targeting Endocannabinoid and Endovanilloid Systems-A Novel Treatment Option for Chronic Pain Management.

Authors:  Natalia Malek; Katarzyna Starowicz
Journal:  Front Pharmacol       Date:  2016-08-17       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.